Cell therapy for spinal cord injury using induced pluripotent stem cells

• Published in: Regenerative therapy Vol. 11; pp. 75 - 80
• Main Authors: Nagoshi, Narihito, Tsuji, Osahiko, Nakamura, Masaya, Okano, Hideyuki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2019; Japanese Society for Regenerative Medicine; Elsevier
• Subjects: Clinical application; Induced pluripotent stem cells; Neural precursor cells; Review; Spinal cord injury; Clinical application; CST; SLA; HMGB1; Spinal cord injury; PBMCs; drNPCs; iPSCs; MLR; OPCs; ASIA; Induced pluripotent stem cells; CiRA; Neural precursor cells; NPCs; SCI; NHPs; GCV; CSPGs; HLA; GSI; C-ABC; ESCs; HSVtk; CiRA, the Center for iPS Cell Research and Application; HLA, human leukocyte antigen; C-ABC, chondroitinase ABC; SCI, spinal cord injury; CSPGs, chondroitin sulfate proteoglycans; NPCs, neural precursor cells; drNPCs, directly reprogrammed neural precursor cells; GSI, γ-secretase inhibitor; HSVtk, herpes simplex virus type I thymidine kinase; CST, corticospinal tract; GCV, ganciclovir; ASIA, American Spinal Injury Association; iPSCs, induced pluripotent stem cells; PBMCs, peripheral blood mononuclear cells; SLA, swine leukocyte antigen; ESCs, embryonic stem cells; MLR, mixed lymphocyte reaction; NHPs, nonhuman primates; HMGB1, high mobility group box-1; OPCs, oligodendrocyte progenitor cells

For the past few decades, spinal cord injury (SCI) has been believed to be an incurable traumatic condition, but with recent developments in stem cell biology, the field of regenerative medicine has gained hopeful momentum in the development of a treatment for this challenging pathology. Among the t...